Innosus (CEO Jaeyong Shim), a startup specializing in medical beauty devices, announced on the 20th that it had secured a total of KRW 14.2 billion in Series A investment from investors including Altos Ventures.
A portion of this investment was made through the sale of existing shares to Tail Ventures, which discovered Innosus at the seed stage. Innosus plans to use the funds to expand into the global aesthetic medical device market and strengthen its R&D capabilities.
Innosus is a medical device company founded in February 2022. It developed 'Alltite', a medical device that applies technology used in cancer treatment to the field of cosmetic lifting.
Oltite emphasizes its internationally patent-pending DLTD (Dermis Layer Targeted Dielectric heating system) technology as its core competitive edge. This technology utilizes dielectric heating principles to intensively heat the mid- to lower-dermis region, minimizing epidermal temperature rise and reducing pain and energy loss. The company claims this reduces pain to a level that allows for procedures without anesthesia.
Additionally, Oltite utilizes a dual-target lifting method that simultaneously targets the dermis and SMAS layers, providing both the tightening effects of RF and the lifting effects of HIFU. Another key feature is its ability to reduce the risk of side effects, such as sagging cheeks, by lowering the concentration of heat in the subcutaneous fat layer.
CEO Shim Jae-yong stated, “This investment is a recognition of Innosus’ technological prowess and global growth potential,” and added, “We plan to use the secured funds to accelerate our entry into the North American, European, and Asian markets and expand our R&D investment for next-generation product development.”
An Altos Ventures official said, “Innosus is a company that combines beauty, manufacturing, and technology, and we decided to invest because we highly value the growth potential that these three elements will create.”
You must be logged in to post a comment.